Nasus Pharma (NSRX) Gains from Investment Securities (2024 - 2025)
Nasus Pharma (NSRX) posted Gains from Investment Securities of $810571.0 for Q4 2025, up 322.83% quarter-over-quarter from $191700.0 in Q4 2024, and up 322.83% year-on-year from $191700.0 in Q4 2024.
Nasus Pharma (NSRX) Gains from Investment Securities (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has reported Gains from Investment Securities for 2 consecutive years, with $810571.0 the latest figure, recorded in Q4 2025.
- Gains from Investment Securities for Q4 2025 came in at $810571.0, up 322.83% year-over-year; the trailing twelve-month figure through Dec 2025 was $810571.0 (up 322.83% YoY), and the FY2025 annual result was $810571.0, up 322.83% from the prior year.
- Gains from Investment Securities was $810571.0 for Q4 2025 at Nasus Pharma, up from $191700.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $810571.0 in Q4 2025 and troughed at $191700.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Nasus Pharma | 28.20 Mn | 23.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 810,571.00 |
| Dec 31, 2025 | 810,571.00 |
| Dec 31, 2024 | 191,700.00 |
| Dec 31, 2024 | 191,700.00 |